The zinc-finger transcription factor Snail1 is inappropriately expressed in breast cancer and associated with poor prognosis. While interrogating human databases, we uncovered marked decreases in relapse-free survival of breast cancer patients expressing high Snail1 levels in tandem with wild-type, but not mutant, p53. Using a Snail1 conditional knockout model of mouse breast cancer that maintains wild-type p53, we find that Snail1 plays an essential role in tumour progression by controlling the expansion and activity of tumour-initiating cells in preneoplastic glands and established tumours, whereas it is not required for normal mammary development. Growth and survival of preneoplastic as well as neoplastic mammary epithelial cells is dependent on the formation of a Snail1/HDAC1/p53 tri-molecular complex that deacetylates active p53, thereby promoting its proteasomal degradation. Our findings identify Snail1 as a molecular bypass that suppresses the anti-proliferative and pro-apoptotic effects exerted by wild-type p53 in breast cancer.
The zinc-finger transcription factor Snail1 is inappropriately expressed in breast cancer and associated with poor prognosis. While interrogating human databases, we uncovered marked decreases in relapse-free survival of breast cancer patients expressing high Snail1 levels in tandem with wild-type, but not mutant, p53. Using a Snail1 conditional knockout model of mouse breast cancer that maintains wild-type p53, we find that Snail1 plays an essential role in tumour progression by controlling the expansion and activity of tumour-initiating cells in preneoplastic glands and established tumours, whereas it is not required for normal mammary development. Growth and survival of preneoplastic as well as neoplastic mammary epithelial cells is dependent on the formation of a Snail1/HDAC1/p53 tri-molecular complex that deacetylates active p53, thereby promoting its proteasomal degradation. Our findings identify Snail1 as a molecular bypass that suppresses the anti-proliferative and pro-apoptotic effects exerted by wild-type p53 in breast cancer.
Oncogenic events precipitate the activation of gene programs that trigger either permanent withdrawal from the cell cycle or apoptosis [1] [2] [3] . The p53 tumour suppressor network is a critical regulator of cellular responses to oncogenic stress, and is a frequent mutational target in human cancers 3 . However, most human breast cancer patients express wild-type p53 and the mechanisms that allow bypass of this critical 'guardian of the genome' during oncogenic transformation remain speculative 3 . Interestingly, recent attention has focused on the function of the zinc-finger (ZF) transcription factor Snail1 in breast cancer [4] [5] [6] [7] [8] [9] . Following its over-expression in transformed mammary epithelial cells (MaECs), Snail1 promotes an epithelial-mesenchymal transition (EMT) program and the acquisition of stem cell-like characteristics while enhancing tumorigenicity [5] [6] [7] [8] [9] [10] [11] [12] . However, Snail1 expression normally falls under the control of complex transcriptional and post-transcriptional regulatory networks 12 , and the role of the endogenously derived gene product in tumour progression remains largely unexplored. As early studies described an association between Snail1 messenger RNA levels and relapse-free survival in breast cancer patients 4 , we re-investigated links between Snail1 mRNA expression and survival in human patients expressing wild-type or mutant p53, while launching efforts to define the role of Snail1 in regulating breast cancer progression in vivo.
RESULTS
Increased Snail1 expression worsens relapse-free survival rates in women with breast cancer in a TP53 wild-type-dependent fashion In female breast cancer patients, TP53 mutations are relegated to a subset of approximately 25% of the disease cohort 3 . While examining relationships between Snail1 mRNA expression levels and clinical outcomes 13, 14 , we noted an inverse relationship between Snail1 levels and relapse-free survival (RFS) in patients expressing wild-type, but not mutant, TP53 (Fig. 1a) . More subtle, but nevertheless, significant associations are also established between Snail1 and distant -metastasis-free survival as well as overall survival in wild-type, but not mutant, TP53 patients (Fig. 1b,c) . Segregating the patient cohort expressing wild-type TP53 into three major molecular subtypes (that is, luminal, HER2
+ and basal breast cancer), a significant association is identified between Snail1 and RFS in luminal, but not basal or HER2 + subtypes (largely a consequence of the limited number of patients with wild-type TP53 in these last groups) ( Fig. 1d and remains controversial [15] [16] [17] [18] [19] , we determined the impact of Snail1 on p53 levels in normal or neoplastic human MaECs expressing either wild-type or mutant TP53. Following transduction with a Snail1 expression vector, wild-type p53 protein levels fall in normal MaECs or breast cancer cells (Fig. 1f,g ). By contrast, exogenously introduced Snail1 did not affect mutant (R280K or R280T) p53 protein levels in human breast carcinoma cells (Fig. 1f,g ). Taken together, these results mirror the status of the patient cohort wherein Snail1-directly or indirectly-serves as a suppressor of wild-type, but not mutant, p53.
Conditional deletion of Snail1 in MaECs restrains the formation and metastatic potential of PyMT-induced mammary tumours
To identify potential roles for endogenously derived Snail1 during tumour progression in vivo, we generated both Snail1
LacZ/wt and Snail1 fl/fl mice [20] [21] [22] [23] , and crossed these transgenic lines into the MMTVPyMT mouse model of breast cancer 24, 25 . MMTV-PyMT transgenic mice exhibit multiple similarities to the luminal B subtype of human breast cancer, and progress from benign hyperplasia to an invasive, poorly differentiated carcinoma that displays a metastatic phenotype 8, 9, [24] [25] [26] . In PyMT-Snail1 LacZ/wt mice, reporter activity is widely detected in hyperplastic lesions and established tumours, but not adjacent normal tissues (Fig. 2a,b) , a finding consistent with Snail1 expression in human breast cancer [27] [28] [29] . Using MMTV-Cre transgenic mice (line F) to target Cre expression in MaECs [30] [31] [32] , we crossed MMTV-Cre;Snail1 fl/fl conditional knockout (cKO) mice with MMTV-PyMT mice to generate female cohorts with the genotypes of MMTV-PyMT;Snail1 fl/fl (designated PyMT-WT mice), MMTV-PyMT;MMTV-Cre;Snail1 fl/wt (PyMT-Het mice), and MMTV-PyMT;MMTV-Cre;Snail1 fl/fl (PyMT-cKO mice). In PyMTcKO;ROSA-LacZ reporter mice, β-galactosidase/LacZ activity is detected in the epithelial compartment of both preneoplastic glands and established tumours, complemented by the absence of Snail1 protein in preneoplastic as well as neoplastic MaECs (Fig. 2c,d and Supplementary Fig. 2a,b) . In PyMT-WT mice, palpable tumours develop in 45-day-old animals with 50% of the mice displaying frank tumour growth by day 60 (Fig. 2e) . In marked contrast, tumour initiation in PyMT-cKO mice is delayed significantly with 50% of targeted mice developing tumours only after 80 days (Fig. 2e) . Relative to PyMT-WT controls, whole-mounts of -cKO mammary glands at 15 weeks of age display significant reductions in tumour size ( Supplementary Fig. 2c ). By 17 weeks of age, while PyMT-WT mice develop multiple tumours, marked reductions in tumour size and number are found in -cKO mice (Fig. 2f,g ). Approximately 9 weeks after the initial detection of mammary tumours, PyMT-WT mice develop large numbers of metastatic lung nodules (Fig. 2h) . By contrast, 9 weeks after palpable tumours develop in PyMT-cKO mice, Snail1 mRNA levels are decreased by ∼80% and few metastatic nodules are detected (see below and Fig. 2h ). Circulating tumour cells also demonstrate a marked decrease in PyMT mRNA levels in blood recovered from PyMT-cKO mice relative to controls (Fig. 2i) . Of note, PyMT mRNA levels in primary tumours from PyMT-WT and -cKO groups are comparable, demonstrating that Snail1 does not affect PyMT expression (Fig. 2i) . Importantly, deleting Snail1 in the normal mammary gland does not affect branching morphogenesis, during either development or pregnancy (Supplementary Fig. 2d ).
Loss of Snail1 in MaECs inhibits expansion and activity of PyMT-induced TICs
Mammary gland whole-mounts prepared from PyMT-WT and -cKO mice were next isolated at hyperplastic/preneoplastic stages of growth (6-8 weeks of age) to determine the impact of Snail1 expression on tumour initiation. MMTV-PyMT induces extensive hyperplasia as early as 6 weeks in WT mice 24, 25 , whereas glands from cKO mice exhibit markedly fewer and smaller hyperplastic lesions (Fig. 3a,b) . By 8 weeks of age, increased numbers of hyperplastic foci are observed in the more distal regions of the mammary gland in PyMT-WT mice relative to -cKO tissues (Fig. 3a,b) .
To define the role of Snail1 in controlling the expansion of transformed MaECs, Lin − epithelial cells were recovered from normal or PyMT preneoplastic mammary glands and profiled using surface markers that distinguish luminal from basal mammary epithelial subsets [33] [34] [35] . Fig. 3c-e) . By contrast, the percentage of the CD29 + CD24 + basal population, which enriches for mammary stem cells in certain tumour models 35 , is markedly decreased in PyMT-WT mammary glands relative to -cKO glands ( Supplementary Fig. 3a Supplementary Fig. 3b,c) .
To assess the effect of Snail1 ablation on TIC status, we isolated preneoplastic mammary epithelial cells (pNECs) from PyMT-WT and -cKO mice, and performed in vitro mammosphere assays. pNECs from PyMT-cKO mice display a marked reduction in mammosphere number and size relative to -WT controls ( Fig. 3f and Supplementary  Fig. 3d ). Furthermore, corroborating our in vitro findings, when limiting numbers of pNECs are injected orthotopically, the PyMTcKO-derived pNECs display reduced TIC potential (Fig. 3g,h ). Similar requirements for Snail1 are observed when preneoplastic mammary luminal progenitor cells (CD29 lo CD24 + ) are recovered from MMTVPyMT;Snail1 fl/fl mice, transduced with adeno-βGal or -Cre in shortterm culture and transplanted orthotopically (Fig. 3i-k) . Snail1 was among the first transcription factors identified to induce EMT 11, 38 , but recent studies have identified key roles for the transcription factor that do not necessarily effect changes in epithelial-mesenchymal characteristics Data are presented as mean ± s.e.m. (n = 6 independent experiments). * * P < 0.01, two-sided Student's t-test. (g,h) pNECs isolated from mammary glands of 6-week-old PyMT-WT or -cKO mice were orthotopically transplanted into nude mouse recipients (n = 5 mice, each), and tumour incidence (g) and volume (h) monitored 9 weeks after transplantation. * * P < 0.01, Mann-Whitney test. (i) Preneoplastic mammary luminal progenitor cells (CD29 lo CD24 + ) isolated from 6-week-old PyMT-WT (that is, PyMT-Snail1 fl/fl ) mice were transduced with adeno-βGal or -Cre in suspension for 2 h. A portion of the transduced cells were cultured in vitro for 48 h, and the cell lysates were collected for RT-PCR to assess the efficiency of Snail1 knockdown. Data are presented as mean ± s.e.m. (n = 5 independent experiments). * * P < 0.01, two-sided Student's t-test. (j,k) A portion of the transduced cells as described in i were immediately transplanted orthotopically into nude mouse recipients (n = 10 mice, each), and tumour incidence (j) and volume (k) were monitored 9 weeks after transplantation. * * P < 0.01, Mann-Whitney test. Source data are provided in Supplementary Table 1 (g,h,j,k).
modest changes in the expression levels of the mesenchymal markers (Fig. 4c) . Cytokeratin-14 (K14)-positive, invasive leader cancer cells have been identified at the tumour-stromal cell interface in both mouse breast cancer models and human patients 26 , and we likewise find that K14 + cells are enriched at the protrusive border of PyMT-WT adenocarcinomas, forming multi-cellular strands that (n = 5 independent experiments). * P < 0.05, * * P < 0.01, two-sided Student's t-test.
invade into the adjacent stromal tissues ( Supplementary Fig. 4a ). By contrast, PyMT-cKO adenocarcinomas fail to display a locally invasive phenotype and the K14 + tumour cells found within tumour masses retain smooth borders with the surrounding stromal interface ( Supplementary Fig. 4a ), a finding consistent with the ability of Snail1 to promote tissue-invasive activity 20, 40 . In addition to triggering EMT, forced expression of Snail1 has been reported to inhibit cell cycle regulation while conferring resistance to pro-apoptotic signals in vitro 11, 38 . Nevertheless, in PyMT-cKO mammary glands, we instead find decreased numbers of proliferative and mitotic cells in 4-week-old preneoplastic as well as neoplastic tissues relative to -WT counterparts (Fig. 4d,e and Supplementary Fig. 4b-e) . PyMT-cKO mammary glands do, however, display increases in pro-apoptotic cells in both hyperplastic and carcinomatous lesions (Fig. 4d,e and Supplementary Fig. 4b-e) .
Snail1 is required to maintain TIC function in established carcinomas
To define the role of Snail1 in maintaining the TIC properties of established carcinomas, LIN − NECs were isolated from late-stage
PyMT-WT carcinomas and transduced with either adeno-βGal or -Cre before orthotopic injection. Under these conditions, tumours are detected at lower frequency in mice that receive 10 2 or 10 3 , but not 10 4 , Snail1-deleted NECs relative to controls (Fig. 5a ). Further, tumours generated from 10 3 , and even 10 4 , Snail1-deleted NECs are dramatically reduced in size relative to controls (Fig. 5b) . As these results suggest that Snail1 is required for maintaining TIC function, we profiled LIN − NECs recovered from control and Snail1-deleted orthotopic tumours for CD24, CD29, CD61 and CD90 expression. Unlike the strikingly distinct CD24/CD29/CD61 profiles observed between PyMT-WT and -cKO preneoplastic glands (Fig. 3c-e) , comparable CD24/CD29/CD61/CD90 profiles are observed when Snail1 is deleted in advanced NECs ( Supplementary  Fig. 5a-d) . Although these differentiation markers are unable to distinguish between NECs recovered from Snail1-intact versusdeleted tumours, aldehyde dehydrogenase (ALDH) activity can serve as a TIC marker in PyMT-induced breast tumours 36 . Indeed, ALDH + cells recovered from orthotopic tumours generated by control NECs exhibit higher tumoursphere-forming activity in vitro relative to ALDH − cells ( Supplementary Fig. 5e-g ). Further, the Fig. 5h,i) . Consistent with this premise, the loss in TIC activity observed following Snail1 deletion in transplantation assays (Fig. 5a,b) correlates with a reduction in the ALDH population ( Supplementary Fig. 5i ). Likewise, when Snail1 is deleted in ALDH + cells recovered from PyMT-Snail1 fl/fl tumours, tumoursphere-forming activity is reduced (Supplementary Fig. 5j ).
To characterize a potential role for Snail1 in maintaining the de-differentiated phenotype of advanced tumours, MMTVPyMT;Snail1 fl/fl NECs were again isolated from 19-week-old mice, transduced with adeno-βGal or adeno-Cre expression vectors in vitro and implanted orthotopically. After 9 weeks, control NECs form poorly differentiated adenocarcinomas (Fig. 5c upper panels) . By contrast, orthotopic tumours derived from Snail1-deleted NECs recover the ability to partially regenerate ductal architecture and re-express β-casein (Fig. 5c lower panels) . Consistent with only minor changes in E-cadherin expression in primary tumours (Fig. 4c) , E-cadherin expression is largely maintained in control orthotopic tumours, although staining intensity is increased in Snail1-deleted transplanted tumours (Fig. 5d) . By contrast, vimentin expression is upregulated in the epithelial compartment of WT control-transplanted orthotopic tumours, but largely restricted to the stroma of Snail1-deleted transplants (Fig. 5d ). Relative to WT controls, freshly isolated tumours retrieved from transplanted Snail1-deleted NECs display significant increases in luminal differentiation markers along with decreased expression of Vim and Fn1 (Fig. 5e ). Consistent with their recovered differentiation status, Snail1-deleted, K14
+ carcinoma cells also lose their tissue-invasive potential in tandem with decreased proliferative potential and increased apoptosis ( Fig. 5f and Supplementary Fig. 6a,b) .
Snail1 acts as a p53 repressor
Given the association between Snail1 mRNA levels and disease outcome in wild-type TP53 breast cancer patients, p53 protein levels were assessed immunohistochemically in PyMT-WT versus -cKO preneoplastic glands. Remarkably, p53 levels are increased dramatically in Snail1-cKO preneoplastic glands with no detected changes in phospho-Rb levels 2,41 ( Fig. 6a and Supplementary Fig. 6c,f) . Similar results are obtained when Snail1 is excised in vitro, the cells injected orthotopically and the transplanted tumours immunostained for p53 and phospho-Rb ( Fig. 6b and Supplementary  Fig. 6c,f) . Although Snail1 can play a role in controlling genomic integrity 42, 43 , Snail1-cKO preneoplastic glands as well as Snail1-deleted orthotopic/primary tumours express comparable levels of p-ATM or γ-H2AX relative to controls ( Supplementary Fig. 6d-g ).
In vitro, while neither adeno-βGal nor adeno-Cre activates p53 expression in PyMT-Snail1 wt/wt or control floxed tumour cells, Snail1-deleted pNECs and NECs increase p53 protein levels, recapitulating the in vivo phenotype (Fig. 6c) . Further, the downstream p53 targets p21 and MDM2 3 are also upregulated with no change in the Rbassociated cyclin kinase inhibitor p16 (Fig. 6c) . Although Snail1 did not affect TP53 expression, both p21 and MDM2 mRNA levels increase significantly in Snail1-deleted cells (Supplementary Fig. 7a ). Concurrently, Snail1 decreases p53 half-life while increasing p53 ubiquitylation ( Supplementary Fig. 7b,c) . Of note, increases in p53 protein levels and activity are also associated with increased levels of p53 acetylation 44 , and following Snail1 deletion, p53 acetylation (Lys379) levels increase (Fig. 6c) . While Snail1-dependent decreases in Lys379 acetylation are consistent with a loss in p53 activity, the protein is acetylated at multiple sites that can each play important roles in regulating p53 function 44 . As such, lysates prepared from Snail1-wild-type or -deleted NECs (containing equalized levels of p53) were subjected to immunoprecipitation using antibodies directed against pan-acetylated lysine (Pan-Ack) or p53. As shown, Snail1-deleted NECs display an increased percentage of acetylated p53 molecules (Fig. 6d) . Immunofluorescence analysis further illustrates an increase in the levels of co-localized p53 and Pan-AcK in Snail1-deleted NECs (Supplementary Fig. 7d) . Importantly, the ability of Snail1 to regulate acetylation-linked events is not limited to p53 as the autocatalytic acetylation of p300, a transcriptional coactivator that acetylates p53 45, 46 , is likewise upregulated in Snail1-deleted pNECs and NECs (Fig. 6c) .
Consistent with an effect of Snail1 on p53 acetylation, p53/Snail1 complexes are found in wild-type NECs with direct binding interactions confirmed using recombinant Snail1 and p53 ( Fig. 6e and Supplementary Fig. 7e ) 17 . By contrast, a common p53 mutation, that is, Arg280 → Lys280, markedly decreases its binding interaction with Snail1 in MDA-MB-231 cells (Supplementary Fig. 7f ). Snail1 is divided into a series of domains that encompass the bulk of its transcriptional repressor activity (that is, the SNAG domain) along with four C 2 H 2 ZFs that recognize consensus E2-box type elements 47 ( Fig. 6f) . Using cells co-expressing epitope-tagged Snail1 or Snail1-deletion mutants and wild-type p53, we identify ZF1 and ZF2 as the dominant p53-binding motifs (Fig. 6f,g ). In complementary studies using p53 deletion mutants, wild-type Snail1 interacts primarily with the DNA-binding domain (DBD) of p53, although N299 p53 mutant retains a weaker, residual binding activity (Fig. 6h,i and Supplementary Fig. 7g ). As expected, wild-type, but not ZF1/2-deleted, Snail1 more effectively represses p53 protein levels in coexpressing cells (Fig. 6j) . Interestingly, SNAG domain-deleted Snail1, despite maintaining its ability to bind p53, fails to retain its full p53-suppressing activity (Fig. 6j) . In considering potential roles for the Snail1 SNAG domain in p53 repression, earlier studies described the ability of this 9-amino-acid motif to recruit the deacetylase HDAC1 48 . Indeed, while wild-type Snail1 binds HDAC1 and p53, the SNAGdeleted mutant completely loses its ability to recruit HDAC1 (Fig. 6k) . Importantly, when cells are co-transfected with both SNAG domaindeleted Snail1 and wild-type Snail1, the p53 repressive effect of wildtype Snail1 is abolished (Fig. 6l) . With regard to the ZF-deletion mutants of Snail1, HDAC1 binding was retained, albeit at lower levels, most likely as a consequence of a decrease in the nuclear import of the Snail1 mutant 49 . The ability of Snail1 to act as a bridging molecule between endogenous p53 and HDAC1 is confirmed in co-immunoprecipitation assays wherein Snail1 deletion almost completely abolishes the recruitment of HDAC1 to p53 (Fig. 6m,n) . Consistent with this model, the HDAC inhibitor TSA 48 blocks the ability of Snail1 to repress p53 levels while inhibiting p53 deacetylation ( Supplementary Fig. 7h) .
A Snail1/p53 axis regulates tumorigenic activity
To determine the degree to which p53 serves as a Snail1 target substrate required for mammary tumour progression, we isolated pNECs from PyMT-cKO glands and assessed the impact of p53 silencing on in vitro tumoursphere as well as in vivo tumorigenic activity. Immunoblot analysis confirms increased levels of p53 in PyMT-cKO cells with p53 expression largely abolished following Snail1/p53 knockdown (Fig. 7a) . Importantly, while Snail1 deletion of p53 mutant plasmids and treated with MG132 (10 µM) for 6 h. Cell lysates were prepared and subjected to co-IP assay. Note the weak band from N299 transfectant. (j) 293T cells were co-transfected with GFP-p53 and FLAGSnail1 (or -deleted mutants) at a ratio of 1:10, and cell lysates were used for immunoblotting. (k) 293T cells were co-transfected with equal amounts of GFP-p53 and FLAG-tagged Snail1 (or -deleted mutants). Cell lysates were prepared and subjected to co-IP assay. (l) 293T cells were co-transfected with GFP-p53, FLAG-Snail1 and HA-Snail1-SNAG at a ratio of 1:10:10, and cell lysates were used for immunoblotting. (m) Lysates from NECs as described in c were subjected to co-IP assay using anti-HDAC1 antibody. (n) A schematic representation of the Snail1/p53/HDAC1 tri-molecular complex with the binding domains responsible for interactions of Snail1-p53 and Snail1-HDAC1. Asterisks and arrows denote IgGs and specific bands with their expected molecular weights, respectively. Results are representative of three (g,i-l) or five (c,d,e,m) independent experiments. Unprocessed original scans of blots are shown in Supplementary Fig. 8 . Source data are provided in Supplementary Table 1 (j) . For quantification, 1,000 to 2,000 cells were counted in 10 random fields of each slide. Data are presented as mean ± s.e.m. (n = 5 independent experiments). * * P < 0.01, one-way ANOVA test. Unprocessed original scans of blots are shown in Supplementary Fig. 8 . Source data are provided in Supplementary Table 1 (c) .
represses tumoursphere-forming activity and tumorigenic potential in vivo, both activities are partially, but significantly, recovered by decreasing p53 levels (Fig. 7b-d) . To directly assess the importance floxed alleles (Fig. 7e) . Remarkably, both the marked reduction in the proliferative activity and the increased pro-apoptotic activity of Snail1-cKO tumours are reversed following TP53 excision (Fig. 7f-h ), thereby identifying p53 as a functionally critical Snail1 target in vivo.
DISCUSSION
Efforts to define roles for EMT-associated transcription factors in cancer have relied largely on model systems wherein Snail1 or related factors were purposefully over-expressed in transformed cell lines 5, [11] [12] [13] . Consequently, the ability and mechanisms by which endogenous Snail1 modulates tumour progression in the in vivo setting-and its relevance to human disease-remain largely undefined 4, 5, [27] [28] [29] 50, 51 .
Having noted an association between Snail1, wild-type TP53 and disease progression in breast cancer patients, we used the MMTVPyMT breast cancer model as a means to interrogate Snail1-wild-type p53 interactions in vivo. As recently reported, Snail1 is upregulated in tumour tissues of MMTV-PyMT mice 8, 9 , but using a β-galactosidase amplifying system, we find a far more global pattern of expression than that observed previously 8, 9 . Further, using a more efficient MMTVCre driver line than that used previously 8 , we find that Snail1 excision markedly impairs the earliest phases of tumour growth and MaEC de-differentiation as well as the generation of TICs. A required role for Snail1 in tumour progression is likewise found to extend to the tumorigenic potential of aggressive adenocarcinomas. Snail1 appears to exert little effect on EMT programs, confirming reports that a complete loss of epithelial characteristics is rarely observed in the MMTV-PyMT model 52, 53 . Of note, Snail1 excision does not affect normal mammary gland development, a finding that dovetails recent work demonstrating that Snail1 expression is largely confined to the mammary gland stroma 9 . However, as Snail1 has recently been shown to modulate intestinal stem cell function 54 , further studies, perhaps using more stem cell-specific Cre-drivers, are needed 55 . Other EMT-inducing transcription factors, including Slug and Twist, have been reported to directly or indirectly affect p53 function in vitro, but the outcome of these interactions has varied [15] [16] [17] [18] [19] [56] [57] [58] [59] [60] [61] . Indeed, p53 has been reported to accelerate the proteasomal degradation of Snail1 or Slug 18, 56, 61 . In our working model (Fig. 6n) , binding interactions between Snail1 and p53 allow SNAG domain-associated HDAC1 to catalyse p53 deacetylation, thereby hastening the functional inactivation of p53. Hence, while most studies emphasize the role of Snail1-HDAC complexes in chromatin remodelling and transcriptional repression 12, 48, 62 , we outline a previously unappreciated role for the deacetylase complex in controlling transcription factor function. Additional effects of Snail1 on the regulation of p300 acetylation as well as p53 transcriptional activity via its interaction with the p53 DNA-binding domain remain to be characterized, but we note that Snail1 can itself undergo acetylation 63 while Snail1 can also be recruited into p53-MDM2 complexes wherein MDM2 itself recruits HDAC1 64 ( Supplementary Fig. 7i ). These results support the existence of a more global-acting acetylation/deacetylation network that jointly controls both Snail1 and p53 function. Finally, it is important to stress that p53 function extends to diverse cellular responses, ranging from cell motility and invasion to the miRNA-dependent control of stem cell formation [65] [66] [67] [68] . As such, the Snail1-dependent regulation of p53 activity probably impacts multiple arms of the carcinoma phenotype. While recent studies have emphasized the ability of EMT-associated transcription factors, including Snail1, to confer chemoresistance to neoplastic cell populations 69, 70 , our studies identify equally important, EMT-independent roles for Snail1 in regulating tumour progression. Given that most breast cancer patients express wild-type TP53, efforts aimed at modulating Snail1-p53 interactions in vivo may exert unexpected therapeutic benefit in this and other neoplastic states.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
Note: Supplementary Information is available in the online version of the paper
Transgenic mouse strains and tumour monitoring. Transgenic mice were housed under standard specific-pathogen-free (SPF) conditions and all research involving animals strictly complied with protocols approved by the Animal Welfare and Ethics Committee (AWEC, China Pharmaceutical University), and the University Committee on Use and Care of Animals (UCUCA, University of Michigan). Mice carrying Snail1 (exon 3) floxed alleles and mice with Snail1-LacZ knockin alleles have been described previously [20] [21] [22] . MMTV-PyMT (stock No. 002374), ROSA26-LacZ (stock No. 003474) and p53 fl/fl (stock No. 008652) transgenic mice were purchased from Jackson Laboratory. MMTV-Cre (line F, stock No. 01XA9) mice were obtained from NCI-Frederick. All mice were on a mixed FVB/C57BL6 background with littermate controls (females) used in all experiments. For spontaneous tumorigenesis studies, weaned females were examined twice a week for the development of mammary tumours by palpation. For metastasis studies, lungs were collected for analysis at 9 weeks post initial detection of palpable tumours, and metastatic nodules counted. The maximal tumour sizes permitted under the approved protocols are 3 cm (length) × 3 cm (width). The investigators were not blinded to allocation during experiments and outcome assessment. No method of randomization was used as mice were segregated into groups based on genotype alone. No statistical method was used to predetermine sample size.
Isolation of Lin − NECs and pNECs and flow cytometry analysis. Isolation of pNECs and NECs was performed as described previously with slight modifications 36 . Briefly, preneoplastic glands or primary tumours were dissected into pieces and dissociated enzymatically at 37 • C for 1 h in culture medium (DMEM/F12) containing 5% FBS, 10 ng ml −1 EGF, 500 ng ml −1 hydrocortisone, 5 mg ml −1 insulin, 20 ng ml −1 cholera toxin and 1% penicillin/streptomycin supplemented with collagenase/hyaluronidase (STEMCELL Technologies). Organoids were harvested and incubated with 0.25% trypsin-EDTA for 2 min, 5 mg ml −1 Dispase plus 0.1 mg ml −1 DNase (Invitrogen) for 5 min, and 0.64% NH 4 ) for 30 min, followed by DAPI staining for 5 min before FACS analysis. All conjugated primary antibodies used for flow cytometry analysis were purchased from BioLegend. In some experiments, ALDH activity of purified cells was measured using a kit from StemCELL Technologies according to the manufacturer's instructions.
Cell culture. All cell lines were purchased from ATCC. 293T, MCF-7 and MDA-MB-231 cells were grown in DMEM. ZR75-1 and CAMA-1 cells were grown in RPMI-1640 and EMEM, respectively. Culture medium was supplemented with 10% heat-inactivated fetal bovine serum and 1% penicillin/streptomycin (all from Invitrogen). Cells were tested for mycoplasma contamination every 2 weeks, and only mycoplasma-negative cells were used. No cell lines in this study were authenticated in our laboratory. No cell lines used in this study were found in the database of commonly misidentified cell lines that is maintained by ICLAC and NCBI Biosample.
Tumorigenesis assay. Nude mice were housed under standard SPF conditions and the animal experiments strictly complied with protocols approved by the Animal Welfare and Ethics Committee (AWEC, China Pharmaceutical University), and the University Committee on Use and Care of Animals (UCUCA, University of Michigan). Fifty microlitres of 1:1 PBS and Matrigel (BD Biosciences) mixture of preneoplastic and neoplastic mammary epithelial cells (pNECs and NECs) at limiting dilutions were transplanted into the fourth mammary glands of 4-weekold nude mice. Mice were examined twice a week for the development of tumours by palpation, and tumour volumes calculated at 7 or 9 weeks after transplantation using the formula V = π× length × width 2 /6. The investigators were not blinded to allocation during experiments and outcome assessment. Mice were randomly allocated to each group by an independent person in the laboratory. No statistical method was used to predetermine sample size.
Clinical data analysis. Patient data were collected from the following databases: E-MTAB-365 (239 samples), E-TABM-43 (37 samples), GSE16446 (68 samples), GSE22093 (65 samples) and GSE3494 (251 samples). Samples were divided as 'high' and 'low' groups by the median of Snail1 expression. Survival was fitted by the 'survfit' function, and Kaplan-Meier curves were drawn by the 'ggsurv' function in the R package 'survival' . Differences between two survival curves were measured by the G-rho family of tests. (Fig. 3d-f and Supplementary Fig. 3 ).
Data availability. Patient data supporting the analyses in Fig. 1 and Supplementary  Fig. 1 are accessed from the public breast cancer data sets EMBL-EBI (accession numbers E-MTAB-365 and E-TABM-43) as well as GEO (accession numbers GSE16446, GSE22093, GSE3494). Statistical source data supporting Figs 3j,h,j,k; 5a,b; 6j; and 7c; and Supplementary Figs 5h; and 7b,i are provided in Supplementary  Table 1 . All other data supporting the findings of this study are available from the corresponding authors on request.
